Form D · Pharmaceuticals

ESSA Pharma Inc.

Vancouver, A1 · CIK 0001633932

Offering snapshot reported Aug 30, 2019 · SEC filing

Reported sold
$36M
Offering amount: $36M
Investors reported
14
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Aug 23, 2019
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 30, 2019Initial$36,000,000No comparison14SEC filing
Apr 1, 2016Initial$4,999,998No comparison2SEC filing
Jan 19, 2016Initial$14,999,992No comparison7SEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06c
Duration over one year
No
Business combination
No
Sales commissions
$2.11M
Finders' fees
$0
Form D file number
021-347780

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Oppenheimer & Co. Inc.249
Bloom Burton & Co.None

Source: Form D, filed Aug 30, 2019. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Raymond Andersen Director, Executive
Franklin Berger Director
Paul Cossum Executive
Richard Glickman Director
John Alex Martin Director
David Parkinson Director, Executive
Frank Perabo Executive
Scott Requadt Director
Marianne Sadar Director, Executive
Gary Sollis Director
Otello Stampacchia Director
Ann Marella Thorell Director
Peter Virsik Executive
David Wood Executive
Sandy Zweifach Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
Suite 720, 999 West Broadway
Vancouver, A1, V5Z 1K5